However, CD38-targeted therapies were associated with higher rates of non-hematologic adverse events, including infections and diarrhea.<h4>Conclusion</h4>CD38 monoclonal antibodies enhance the depth of response and prolong progression-free survival in multiple myeloma, with an acceptable safety profile, supporting their integration into treatment algorithms. This evidence concerns the gene CD38 and AL amyloidosis.